Trials
2 active
5 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “This is a study for adults with a lung disease called idiopathic pulmonary fibrosis. The main purpose of this study is to look at how well deupirfenidone improves lung function and how safe it is for people with idiopathic pulmonary fibrosis (IPF) when compared with pirfenidone. Participants may have been treated with an approved antifibrotic drug for up to a year in the past, but they cannot be on background antifibrotic treatment during this study. Participants will be randomly assigned (meaning by chance) to take either deupirfenidone or pirfenidone 3 times a day, and neither a participant…”In the company’s words, NCT07284602 on ClinicalTrials.gov
- Other names
- LYT-100
Other drugs for Idiopathic Pulmonary Fibrosis (IPF)
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up1
- Nov 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2029 | Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 2Active, not recruiting | 15 Oct 2024 | LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 2Terminated | 28 Jun 2022 | LYT-100 in Post-acute COVID-19 Respiratory Disease | |
| Phase 2Terminated | 9 Sep 2022 | LYT-100 in Patients With BCRL | |
| Phase 1Completed | 1 Jan 2022 | PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026